MM&M

Ionis’ long-term HAE drug lowered attack rates, topline Phase 3 results show

Initial findings from a Phase 3 efficacy trial suggest Ionis Pharmaceuticals’ RNA-targeted treatment, given monthly or bimonthly, cut angioedema attacks more than placebo, the firm said Monday. The ...
Hosted on MSN

Pharvaris stock gains on HAE drug meeting late-stage study goals

Shares of Pharvaris PHVS rose nearly 22% on Wednesday after the company announced positive results from the phase III RAPIDe-3 study evaluating its lead pipeline drug deucrictibant in the hereditary ...
Seeking Alpha

KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning

KalVista Pharmaceuticals, Inc. (KALV) had achieved a huge win announced just the other day on July 7th of 2025, whereby the FDA had approved its oral on-demand Hereditary Angioedema [HAE] plasma ...
MM&M

Intellia’s CRISPR-based drug for HAE passes Phase 1 test

NTLA-2002, Intellia Therapeutics’ CRISPR-based treatment for hereditary angioedema (HAE), continues to look durable through Phase 1, the company said Monday. The single-dose treatment was associated ...
Healthline

How Is Hereditary Angioedema Diagnosed?

Hereditary angioedema (HAE) is a rare genetic disorder that causes episodes of severe swelling throughout your body. It is caused by abnormal immune responses. But unlike allergic swelling, HAE is not ...